# A flexible approach to time-to-event data analysis using case-base sampling

Jesse Islam McGill University July 11, 2019 • Meet Justin.

- Meet Justin.
  - Age: 56

- Meet Justin.
  - Age: 56
  - Worried about his prostate.

- Meet Justin.
  - Age: 56
  - Worried about his prostate.
  - What is Justin's two year risk of death due to prostate cancer?

 In disease etiology, we tend to make use of the proportional hazards hypothesis.

- In disease etiology, we tend to make use of the proportional hazards hypothesis.
  - Cox Regression

- In disease etiology, we tend to make use of the proportional hazards hypothesis.
  - Cox Regression
- When we want the absolute risk:

- In disease etiology, we tend to make use of the proportional hazards hypothesis.
  - Cox Regression
- When we want the absolute risk:
  - Parametric models

- In disease etiology, we tend to make use of the proportional hazards hypothesis.
  - Cox Regression
- When we want the absolute risk:
  - Parametric models
  - Breslow estimator

 Julien and Hanley found that survival analysis rarely produces prognostic functions, even though the software is widely available in cox regression packages. [1]

- Julien and Hanley found that survival analysis rarely produces prognostic functions, even though the software is widely available in cox regression packages. [1]
- They believe the stepwise nature is the reason, as it reduces interpretability. [1]

- Julien and Hanley found that survival analysis rarely produces prognostic functions, even though the software is widely available in cox regression packages. [1]
- They believe the stepwise nature is the reason, as it reduces interpretability. [1]
- Want to easily model non-proportional hazards. [1]

- Julien and Hanley found that survival analysis rarely produces prognostic functions, even though the software is widely available in cox regression packages. [1]
- They believe the stepwise nature is the reason, as it reduces interpretability. [1]
- Want to easily model non-proportional hazards. [1]
- A streamlined approach for reaching a **smooth absolute risk** curve. [1]

**Reid**: How do you feel about the cottage industry that's grown up around it [the Cox model]?

**Cox**: Don't know, really. In the light of some of the further results one knows since, I think I would normally want to tackle problems parametrically, so I would take the underlying hazard to be a Weibull or something. I'm not keen on nonparametric formulations usually.

**Reid**: So if you had a set of censored survival data today, you might rather fit a parametric model, even though there was a feeling among the medical statisticians that that wasn't quite right.

**Cox**: That's right, but since then various people have shown that the answers are very insensitive to the parametric formulation of the underlying distribution [see, e.g., Cox and Oakes, Analysis of Survival Data, Chapter 8.5]. And if you want to do things like predict the outcome for a particular patient, it's much more convenient to do that parametrically.

# European Randomized Study of Prostate Cancer Screening (ERSPC) Data

•  $\sim 150\ 000\ men\ ages\ 55-69.\ [4]$ 

#### The European Randomized Study of Screening for Prostate Cancer – Prostate Cancer Mortality at 13 Years of Follow-up

Fritz H. Schröder<sup>1</sup>, Jonas Hugosson<sup>2</sup>, Monique J. Roobol<sup>1</sup>, Teuvo L.J. Tammela<sup>3</sup>, Marco Zappa<sup>4</sup>, Vera Nelen<sup>5</sup>, Maciej Kwiatkowski<sup>6,7</sup>, Marcos Lujan<sup>8,9</sup>, Lissa Määttänen<sup>10</sup>, Hans Lilja<sup>11,12,13</sup>, Louis J. Denis<sup>14</sup>, Franz Recker<sup>6</sup>, Alvaro Paez<sup>15,16</sup>, Chris H. Bangma<sup>1</sup>, Sigrid Carlsson<sup>2,11</sup>, Donella Puliti<sup>4</sup>, Arnauld Villers<sup>17</sup>, Xavier Rebillard<sup>18</sup>, Matti Hakama<sup>10,19</sup>, Ulf-Hakan Stenman<sup>20</sup>, Paula Kujala<sup>21</sup>, Kimmo Taari<sup>22</sup>, Gunnar Aus<sup>23</sup>, Andreas Huber<sup>24</sup>, Theo van der Kwast<sup>25</sup>, Ron H.N. van Schaik R<sup>26</sup>, Harry J. de Koning<sup>27</sup>, Sue M. Moss<sup>28</sup>, Anssi Auvinen<sup>19</sup>, and for the ERSPC Investigators

# European Randomized Study of Prostate Cancer Screening (ERSPC) Data

- $\sim 150\ 000\ men\ ages\ 55-69.\ [4]$
- Examined effects screening has on death due to prostate cancer. [4]

### The European Randomized Study of Screening for Prostate Cancer – Prostate Cancer Mortality at 13 Years of Follow-up

Fritz H. Schröder<sup>1</sup>, Jonas Hugosson<sup>2</sup>, Monique J. Roobol<sup>1</sup>, Teuvo L.J. Tammela<sup>3</sup>, Marco Zappa<sup>4</sup>, Vera Nelen<sup>5</sup>, Maciej Kwiatkowski<sup>6,7</sup>, Marcos Lujan<sup>8,9</sup>, Lissa Määttänen<sup>10</sup>, Hans Lilja<sup>11,12,13</sup>, Louis J. Denis<sup>14</sup>, Franz Recker<sup>6</sup>, Alvaro Paez<sup>15,16</sup>, Chris H. Bangma<sup>1</sup>, Sigrid Carlsson<sup>2,11</sup>, Donella Puliti<sup>4</sup>, Arnauld Villers<sup>17</sup>, Xavier Rebillard<sup>18</sup>, Matti Hakama<sup>10,19</sup>, Ulf-Hakan Stenman<sup>20</sup>, Paula Kujala<sup>21</sup>, Kimmo Taari<sup>22</sup>, Gunnar Aus<sup>23</sup>, Andreas Huber<sup>24</sup>, Theo van der Kwast<sup>25</sup>, Ron H.N. van Schaik R<sup>26</sup>, Harry J. de Koning<sup>27</sup>, Sue M. Moss<sup>28</sup>, Anssi Auvinen<sup>19</sup>, and for the ERSPC Investigators

#### head(casebase::ERSPC)

PatientID	ScrArm	Follow.Up.Time	DeadOfPrCa
1	1	0.003	0
2	0	1.038	1
3	1	7.966	1
4	0	11.975	1
5	1	14.910	0

 Using the ERSPC dataset and casebase, we will determine Justin's absolute risk for death by prostate cancer. 1. Clever sampling.

- 1. Clever sampling.
- 2. Allows a parametric fit using *logistic regression*.

- 1. Clever sampling.
- 2. Allows a parametric fit using logistic regression.
- Casebase is parametric, and allows different parametric fits by incorporation of the time component.

- 1. Clever sampling.
- 2. Allows a parametric fit using *logistic regression*.
- Casebase is parametric, and allows different parametric fits by incorporation of the time component.
- Package contains an implementation for generating population-time plots.

# Casebase: Sampling [5]



# Casebase: Sampling [5]



Follow-up time (years)

### Casebase: Sampling [5]



### **Casebase: Sampling**

casebase::popTime(Data,Event,Time)



Follow-up time (years)

# Casebase: Sampling [3]



Follow-up time (years)

• We can now fit models of the form: [1]

$$log(h(t; \alpha, \beta)) = g(t; \alpha) + \beta X$$

• We can now fit models of the form: [1]

$$log(h(t; \alpha, \beta)) = g(t; \alpha) + \beta X$$

 By changing the function g(t; α), we can model different parametric families easily: *Exponential*:  $g(t; \alpha)$  is equal to a constant

casebase::fitSmoothHazard(status ~ X1 + X2)

Gompertz:  $g(t; \alpha) = \alpha t$ 

casebase::fitSmoothHazard(status ~ time + X1 + X2)

Weibull:  $g(t; \alpha) = \alpha \log(t)$ 

casebase::fitSmoothHazard(status ~ log(time) + X1 + X2)

#### Death by prostate cancer: hazard ratios

```
call:
glm(formula = formula, family = binomial, data = sampleData)
Deviance Residuals:
   Min
             1Q Median
                              30
                                      Max
-0.2693 -0.1715 -0.1348 -0.0908 4.5189
Coefficients:
                   Estimate Std. Error z value Pr(>|z|)
(Intercept)
                 -9.46535 0.15812 -59.862 <2e-16 ***
log(Follow.Up.Time) 1.08124 0.08264 13.084 <2e-16 ***
ScrArm
                  -0.20833 0.08859 -2.352 0.0187 *
_ _ _
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
   Null deviance: 6059.0 on 54539 degrees of freedom
Residual deviance: 5794.1 on 54537 degrees of freedom
ATC: 5800.1
Number of Fisher Scoring iterations: 8
```

Model	Hazard Ratio	Std.Error
Cox	0.801	1.092
Gompertz	0.802	1.093
Exponential	0.810	1.092
Weibull	0.797	1.093

• We have parametric hazard models now.

- We have parametric hazard models now.
- To get the absolute risk, we need to evaluate the following equation in relation to the hazard:

$$CI(x,t) = 1 - e^{-\int_0^t h(x,u)du}$$

- We have parametric hazard models now.
- To get the absolute risk, we need to evaluate the following equation in relation to the hazard:

$$CI(x,t) = 1 - e^{-\int_0^t h(x,u)du}$$

*CI(x,t)*= Cumulative Incidence (Absolute Risk)
- We have parametric hazard models now.
- To get the absolute risk, we need to evaluate the following equation in relation to the hazard:

$$CI(x,t) = 1 - e^{-\int_0^t h(x,u)du}$$

- *CI(x,t)*= Cumulative Incidence (Absolute Risk)
- h(x,u)= Hazard function

- We have parametric hazard models now.
- To get the absolute risk, we need to evaluate the following equation in relation to the hazard:

$$CI(x,t) = 1 - e^{-\int_0^t h(x,u)du}$$

- *Cl(x,t)*= Cumulative Incidence (Absolute Risk)
- h(x,u)= Hazard function
- Lets use the weibull hazard.

#### casebase::absoluteRisk(fit, time=2, covariate\_profile)



 Casebase sampling permits the use of GLMs and the tools associated with them

- Casebase sampling permits the use of GLMs and the tools associated with them
- The casebase package contains tools to generate:

- Casebase sampling permits the use of GLMs and the tools associated with them
- The casebase package contains tools to generate:
  - Population-Time plots

- Casebase sampling permits the use of GLMs and the tools associated with them
- The casebase package contains tools to generate:
  - Population-Time plots
  - Hazard functions

- Casebase sampling permits the use of GLMs and the tools associated with them
- The casebase package contains tools to generate:
  - Population-Time plots
  - Hazard functions
  - Absolute Risk

- Casebase sampling permits the use of GLMs and the tools associated with them
- The casebase package contains tools to generate:
  - Population-Time plots
  - Hazard functions
  - Absolute Risk
- Flexible fits through splines.

- Casebase sampling permits the use of GLMs and the tools associated with them
- The casebase package contains tools to generate:
  - Population-Time plots
  - Hazard functions
  - Absolute Risk
- Flexible fits through splines.
- Casebase can deal with competing risks.

1.Hanley, James A, and Olli S Miettinen. 2009. "Fitting Smooth-in-Time Prognostic Risk Functions via Logistic Regression." *The International Journal of Biostatistics 5 (1).* 

2.Saarela, Olli. 2015. "A Case-Base Sampling Method for Estimating Recurrent Event Intensities." *Lifetime Data Analysis*. Springer, 1–17

3.Saarela, Olli. Case-Base Sampling for Fitting and Validating Prognostic Models. 8 Nov. 2014, www.fields.utoronto.ca/programs/scientific/14-15/biomarker/slides/saarela.pdf. 4.Schroder FH, et al., for the ERSPC Investigators.Screening and Prostate-Cancer Mortality in a Randomized European Study. *N Engl J Med* 2009;360:1320-8.

5.Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. *Bone Marrow Transplant*. 2007 Aug;40(4):381-7. doi: 10.1038/sj.bmt.1705727.

6.Turgeon, M. (2017, June 10). Retrieved May 05, 2019, from https://www.maxturgeon.ca/slides/ MTurgeon-2017-Student-Conference.pdf

## Tutorial:

# http://sahirbhatnagar.com/casebase/

Slides:

https://github.com/Jesse-Islam/UseR–CaseBase-Presentation Questions?

# APPENDIX

• Current methods:

- Current methods:
  - Fine-Gray

- Current methods:
  - Fine-Gray
  - Kaplan-Meier

- Current methods:
  - Fine-Gray
  - Kaplan-Meier
- Proposed method:

- Current methods:
  - Fine-Gray
  - Kaplan-Meier
- Proposed method:
  - Case-Base

Two diseases:

D	Status	ftime
ALL	2	0.67
AML	1	9.50
ALL	0	131.77
ALL	2	24.03

- Two diseases:
  - Acute Lymphoblastic Leukemia (ALL)

D	Status	ftime
ALL	2	0.67
AML	1	9.50
ALL	0	131.77
ALL	2	24.03

- Two diseases:
  - Acute Lymphoblastic Leukemia (ALL)
  - Acute Myeloblastic Leukemia (AML)

D	Status	ftime
ALL	2	0.67
AML	1	9.50
ALL	0	131.77
ALL	2	24.03

- Two diseases:
  - Acute Lymphoblastic Leukemia (ALL)
  - Acute Myeloblastic Leukemia (AML)
- Contains a competing event.

Status	ftime
2	0.67
1	9.50
0	131.77
2	24.03
	2 1 0

# Competing Risks: Absolute Risk

